Categories: Latest

Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea

Tokyo, October 01, 2020: Eisai Co., Ltd. and Seikagaku Corporation announced today that the companies have entered into an agreement for the marketing alliance in South Korea for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. Eisai and Seikagaku signed an agreement for the co-development and marketing alliance in China of SI-613 on April 1, 2020. Thus, South Korea becomes the second country for the companies to conclude the marketing alliance for SI-613.

On the basis of this agreement, Eisai Korea Inc., Eisai’s subsidiary in South Korea, will acquire exclusive marketing rights for SI-613 in South Korea and apply for the manufacturing and marketing approval thereof. After obtaining approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution. Eisai will pay Seikagaku the upfront payment and sales milestones.

Osteoarthritis is a disease caused by the articular cartilage damage due to aging and other factors, leading to inflammation and pain, which result in impaired quality of life (QOL). Knee osteoarthritis is one of the most frequent cases among the diseases thereof, and the number of patients with knee osteoarthritis in South Korea is estimated to be approximately 3.2 million.(1) It is anticipated that the number will continue to increase as the population ages.

SI-613 is diclofenac conjugated sodium hyaluronate created by Seikagaku using their proprietary drug-binding technology to chemically bond hyaluronic acid and diclofenac (an anti-inflammatory drug). This material has the analgesic and anti-inflammatory effects of diclofenac, which is designed to be sustained-released(2) by a drug delivery system(3), in addition to the joint function improving effect of sodium hyaluronate. Hence, it is expected that SI-613 rapidly and continuously reduces the pain and inflammation associated with osteoarthritis.

Under this agreement, Eisai aims to meet the unmet medical needs of patients with knee osteoarthritis by utilizing the knowledge and networks that Eisai has cultivated through its Korea business. Seikagaku will seek to maximize the value of SI-613 in South Korea by leveraging Eisai’s business base in South Korea.

Through the commercialization of SI-613, the companies will provide new treatment options in South Korea for knee osteoarthritis and contribute to improving the QOL of patients.

Corporate Comm India (CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

7 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago